Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

313 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.
Westphalen CB, Federer-Gsponer J, Pauli C, Karapetyan AR, Chalabi N, Durán-Pacheco G, Beringer A, Bochtler T, Cook N, Höglander E, Jin DX, Losa F, Mileshkin L, Moch H, Ross JS, Sokol ES, Tothill RW, Krämer A. Westphalen CB, et al. Among authors: mileshkin l. ESMO Open. 2023 Dec;8(6):102035. doi: 10.1016/j.esmoop.2023.102035. Epub 2023 Nov 2. ESMO Open. 2023. PMID: 37922692 Free PMC article.
Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis.
Moran S, Martínez-Cardús A, Sayols S, Musulén E, Balañá C, Estival-Gonzalez A, Moutinho C, Heyn H, Diaz-Lagares A, de Moura MC, Stella GM, Comoglio PM, Ruiz-Miró M, Matias-Guiu X, Pazo-Cid R, Antón A, Lopez-Lopez R, Soler G, Longo F, Guerra I, Fernandez S, Assenov Y, Plass C, Morales R, Carles J, Bowtell D, Mileshkin L, Sia D, Tothill R, Tabernero J, Llovet JM, Esteller M. Moran S, et al. Among authors: mileshkin l. Lancet Oncol. 2016 Oct;17(10):1386-1395. doi: 10.1016/S1470-2045(16)30297-2. Epub 2016 Aug 27. Lancet Oncol. 2016. PMID: 27575023
Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion.
McEvoy CR, Xu H, Smith K, Etemadmoghadam D, San Leong H, Choong DY, Byrne DJ, Iravani A, Beck S, Mileshkin L, Tothill RW, Bowtell DD, Bates BM, Nastevski V, Browning J, Bell AH, Khoo C, Desai J, Fellowes AP, Fox SB, Prall OW. McEvoy CR, et al. Among authors: mileshkin l. J Clin Invest. 2019 May 1;129(5):1940-1945. doi: 10.1172/JCI123089. Epub 2019 Mar 5. J Clin Invest. 2019. PMID: 30835257 Free PMC article.
FAPI PET/CT: Will It End the Hegemony of 18F-FDG in Oncology?
Hicks RJ, Roselt PJ, Kallur KG, Tothill RW, Mileshkin L. Hicks RJ, et al. Among authors: mileshkin l. J Nucl Med. 2021 Mar;62(3):296-302. doi: 10.2967/jnumed.120.256271. Epub 2020 Dec 4. J Nucl Med. 2021. PMID: 33277397 Free article.
A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience.
Pauli C, Bochtler T, Mileshkin L, Baciarello G, Losa F, Ross JS, Pentheroudakis G, Zarkavelis G, Yalcin S, Özgüroğlu M, Beringer A, Scarato J, Mueller-Ohldach M, Thomas M, Moch H, Krämer A. Pauli C, et al. Among authors: mileshkin l. Oncologist. 2021 May;26(5):e769-e779. doi: 10.1002/onco.13744. Epub 2021 Mar 25. Oncologist. 2021. PMID: 33687747 Free PMC article. Clinical Trial.
313 results